Quoin Pharmaceuticals
Tracked across 3 events · 19 articles · First seen Jul 09, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Quoin Pharmaceuticals received FDA IND clearance for QRX003 in Peeling Skin Syndrome, enabling a Phase 2 study. The company's stock fell over 8% in pre-market trading, reflecting mixed market sentiment.
Jul 09, 2026 · 7 articles
Business
Impact: Quoin Pharmaceuticals is the issuer in this private placement, raising up to $50 million to fund operations and clinical development. The financing strengthens its balance sheet and extends its cash runway into 2029.
Aug 28, 2026 · 6 articles
Regulatory
On September 8, 2026, the U.S. United States — Food and Drug Administration granted Rare Pediatric Disease (RPD) Designation to Quoin Pharmaceuticals' lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS). This is…
Impact: Quoin is the developer of QRX003 and the recipient of the RPD designation, which strengthens its pipeline and potential for PRV-derived value.
Sep 08, 2026 · 6 articles
100
United States — Food and Drug Administration granted designation Quoin PharmaceuticalsFDA grants RPD designation...
ERGEN INTELLIGENCE
Track Quoin Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard